Giovanni Palazzo

National Information Campaign Revealed Disease Characteristic and Burden in Adult Patients Suffering from Atopic Dermatitis

G. Fabbrocini, K. Peris, G. Pellacani, 2022, Journal of clinical medicine.

Effectiveness and Safety of Upadacitinib in the Treatment of Moderate-Severe Atopic Dermatitis: A Multicentric, Prospective, Real-World, Cohort Study

G. Fabbrocini, K. Peris, A. Costanzo, 2022, Drugs in R&D.

Long-term Efficacy and Safety of Secukinumab in Real Life: a 240 Weeks Multicenter Study from Southern Italy.

G. Fabbrocini, M. Megna, C. Patruno, 2023, The Journal of dermatological treatment.

Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation.

G. Fabbrocini, M. Napolitano, K. Peris, 2023, American journal of clinical dermatology.